Literature DB >> 8587757

Value of quantitative salivary gland scintigraphy in the early stage of Sjögren's syndrome.

K H Bohuslavizki1, W Brenner, H Wolf, C Sippel, G Tönshoff, S Tinnemeyer, M Clausen, E Henze.   

Abstract

The aim of this study was to test the impact of quantitative salivary gland scintigraphy in patients with suspected Sjögren's syndrome. Thirteen patients with suspected Sjögren's syndrome were investigated. During clinical work-up, three had severe and four had mild Sjögren's syndrome, while six were normal. Quantitative salivary gland scintigraphy was performed using a standardized method. The normal data-base consisted of 172 patients without any evidence of salivary gland malfunction. Visual and quantitative comparisons of the patients' scintigrams were made. In the patients with severe Sjögren's syndrome, uptake was 0.10 +/- 0.04% and 0.09 +/- 0.03% in the parotid and submandibular glands respectively, confirming the visual diagnosis. In the patients without Sjögren's syndrome, concordance between the visual and quantitative evaluations could also be shown. In contrast, among the patients with mild Sjögren's syndrome, uptake was diminished (P < 0.05), amounting to 0.21 +/- 0.05% and 0.16 +/- 0.02% in the parotid and submandibular glands respectively, while visual analysis indicated normal parenchymatous function. In conclusion, quantitative salivary gland scintigraphy is essential for the reliable detection of parenchymatous malfunction at an early stage of Sjögren's syndrome, which may be missed by visual analysis alone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587757     DOI: 10.1097/00006231-199511000-00007

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Correlations between histopathologic and scintigraphic parameters of salivary glands in patients with Sjögren's syndrome.

Authors:  Tamer Aksoy; Pinar Ozgen Kiratli; Belkis Erbas
Journal:  Clin Rheumatol       Date:  2012-06-26       Impact factor: 2.980

Review 2.  Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Zhongxin Jiang; Guoming Wang; Shuyao Zuo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-04       Impact factor: 9.236

3.  Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.

Authors:  K H Bohuslavizki; S Klutmann; C Bleckmann; W Brenner; S Lassmann; J Mester; E Henze; M Clausen
Journal:  Strahlenther Onkol       Date:  1999-02       Impact factor: 3.621

4.  Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumours.

Authors:  I H Liem; R A Olmos; A J Balm; R B Keus; H van Tinteren; R P Takes; S H Muller; A M Bruce; C A Hoefnagel; F J Hilgers
Journal:  Eur J Nucl Med       Date:  1996-11

5.  Morphometric and functional changes of salivary gland dysfunction after radioactive iodine ablation in a murine model.

Authors:  Jeong-Seok Choi; In Suh Park; Seok-Ki Kim; Jae-Yol Lim; Young-Mo Kim
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

6.  Imaging Activated-T-Lymphocytes in the Salivary Glands of Patients with Sjögren's Syndrome by 99mTc-Interleukin-2: Diagnostic and Therapeutic Implications.

Authors:  Giuseppe Campagna; Luz Kelly Anzola; Michela Varani; Chiara Lauri; Guido Gentiloni Silveri; Lorenzo Chiurchioni; Francesca Romana Spinelli; Roberta Priori; Fabrizio Conti; Alberto Signore
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.